Literature DB >> 14556428

Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy.

Mike Youle1, Mark A Wainberg.   

Abstract

Chemoprophylaxis may be a prevention strategy for the sexual transmission of human immunodeficiency virus (HIV). Evidence suggests that condom use has waned with the availability of antiretroviral medication, at least in some resource-rich settings. Barrier methods of HIV prevention have inherent problems, and the potential for failure. Microbicide research has focused primarily on male-to-female transmission. Analogous to post-exposure prophylaxis, HIV prevention may be achieved by pre-exposure prophylaxis in some settings. Research in this potential strategy may be rewarding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556428     DOI: 10.1177/154510970300200302

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  14 in total

Review 1.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

2.  Socioecological influences on community involvement in HIV vaccine research.

Authors:  Paula M Frew; Matthew Archibald; Brooke Hixson; Carlos del Rio
Journal:  Vaccine       Date:  2011-06-29       Impact factor: 3.641

3.  Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations.

Authors:  J T Galea; J J Kinsler; X Salazar; S-J Lee; M Giron; J N Sayles; C Cáceres; W E Cunningham
Journal:  Int J STD AIDS       Date:  2011-05       Impact factor: 1.359

4.  Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colorado.

Authors:  Alia A Al-Tayyib; Mark W Thrun; Jason S Haukoos; N Eugene Walls
Journal:  AIDS Behav       Date:  2014-04

5.  Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.

Authors:  Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

6.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

7.  An extended model of reasoned action to understand the influence of individual- and network-level factors on African Americans' participation in HIV vaccine research.

Authors:  Paula M Frew; Matthew Archibald; Dazon Dixon Diallo; Su-I Hou; Takeia Horton; Kayshin Chan; Mark J Mulligan; Carlos del Rio
Journal:  Prev Sci       Date:  2010-06

8.  Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection.

Authors:  Frits van Griensven; Warunee Thienkrua; Wichuda Sukwicha; Wipas Wimonsate; Supaporn Chaikummao; Anchalee Varangrat; Philip A Mock
Journal:  J Int AIDS Soc       Date:  2010-04-14       Impact factor: 5.396

Review 9.  The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention.

Authors:  Mary Jane Rotheram-Borus; Dallas Swendeman; Gary Chovnick
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

10.  HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Authors:  A David Paltiel; Kenneth A Freedberg; Callie A Scott; Bruce R Schackman; Elena Losina; Bingxia Wang; George R Seage; Caroline E Sloan; Paul E Sax; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.